Relation of "lymphoid" phenotype and response to chemotherapy incorporating vincristine-prednisolone in the acute phase of Ph1 positive leukemia.
George Janossy,R K Woodruff,M. J. Pippard,Grant Prentice,A. Victor Hoffbrand,Ann Paxton,T. Andrew Lister,Christopher Bunch,Mel Greaves +8 more
Reads0
Chats0
TLDR
The clinical course of the ALL+ patients was variable: eight patients remitted with return to the appearances of the chronic phase; four patients demonstrated elimination of the Ph1 positive clone with hypoplasia and this was followed by normal marrow regeneration in two; Subsequent relapse was of either the All+ “lymphoid” or the ALL− myeloid type.Abstract:
Forty-four patients with Ph1 positive leukemia (36 developing blast crisis after chronic phase and eight presenting in acute leukemia) were classified into sub-groups on the basis of reactivity of blasts with an anti-serum made against non-T,non-B acute lymphoid leukemia (ALL+), levels of terminal transferase enzyme (TdT+) and morphology. Positivity with anti-ALL serum was the most sensitive and reliable marker, and TdT was an important aid. The presence of “lymphoid” blasts in blast crisis of CML was related to the response to chemotherapy incorporating Vincristine and Prednisolone (VP). Patients with ALL+ blasts frequently (14 of 15 cases) responded to therapy while 21 of 25 patients who had no ALL+ blasts failed to respond. The clinical course of the ALL+ patients was variable: eight patients remitted with return to the appearances of the chronic phase; four patients demonstrated elimination of the Ph1 positive clone with hypoplasia and this was followed by normal (Ph1 negative) marrow regeneration in two. Subsequent relapse was of either the ALL+ “lymphoid” or the ALL− myeloid type. A regimen incorporating VP should be the treatment of choice in “lymphoid” blast crisis of CML. Cancer 43:426-434, 1979.read more
Citations
More filters
Journal ArticleDOI
Imatinib Mesylate — A New Oral Targeted Therapy
David G. Savage,Karen H. Antman +1 more
TL;DR: This review discusses the development and uses of imatinib mesylate, a protein tyrosine kinase inhibitor useful in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors that was recently approved by the Food and Drug Administration.
Journal ArticleDOI
Immunologic classification of leukemia and lymphoma.
Kenneth A. Foon,Robert F. Todd +1 more
TL;DR: It is now clear that acute lymphoblastic leukemia (ALL) is heterogeneous and monoclonal antibodies that identify B cells, such as the anti-B1 andAnti-B4 antibodies in combination with studies of immunoglobulin gene rearrangement, have demonstrated that virtually all cases of non-T-ALL are malignancies of B cell origin.
Journal ArticleDOI
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients
Hagop M. Kantarjian,Michael J. Keating,Moshe Talpaz,Ronald S. Walters,Terry L. Smith,Ann Cork,Kenneth B. McCredie,Emil J. Freireich +7 more
TL;DR: The beneficial association of therapy with survival was demonstrated by the significantly longer median survival of patients treated since 1981 compared with those treated earlier, even after accounting for the pretreatment prognostic factors, and by the significant improvement in survival of Patients achieving remission using the "landmark" analysis technique.
Journal ArticleDOI
Chronic myelogenous leukemia--new concepts (first of two parts).
Koeffler Hp,Golde Dw +1 more
TL;DR: A large number of patients diagnosed with chronic myelogenous leukemia with a marked prophylactic response to chemotherapy also have a history of atypical Irving's disease.
Journal ArticleDOI
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage
Jerome Ritz,Lee M. Nadler,Atul K. Bhan,Jean Notis-McConarty,John M. Pesando,Stuart F. Schlossman +5 more
TL;DR: Results indicate that expression of CALLA is not limited to relatively undifferentiated leukemic lymphoblasts but also occurs in more differentiated lymphoid malignancies, however, normal differentiated lymphoids cells in lymph node, spleen, and thymus, which have a phenotype similar to that of lymphoma cells, do not appear to express CALLA.
References
More filters
Journal ArticleDOI
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
Richard Peto,M.C. Pike,P. Armitage,N. E. Breslow,David Cox,S V Howard,N Mantel,Klim McPherson,Julian Peto,Pete Smith +9 more
TL;DR: Efficient methods of analysis of randomized clinical trials in which the authors wish to compare the duration of survival among different groups of patients are described.
Journal ArticleDOI
Chromosome preparations of bone marrow cells without prior in vitro culture or in vivo colchicine administration.
J. H. Tjio,J. Whang +1 more
TL;DR: Bone marrow from au erythropoietic region is freed of blood clots by washing 1-3 min in 1 μg/ml colchicine solution and soaking 1-2 hr at 20-30° C in a second change to carry out the hypotonic treatment and subsequent fixation in Carnoy's solution I.
Journal ArticleDOI
Antisera to acute lymphoblastic leukemia cells.
TL;DR: It is concluded that antisera to ALL may define an antigen which may be restricted in expression to a large subgroup of ALL cases, and which offers considerable diagnostic and prognostic potential.
Journal ArticleDOI
Terminal deoxynucleotidyl transferase activity in human leukemic cells and in normal human thymocytes.
TL;DR: Peripheral leukocytes from patients with and without leukemia were assayed for presence of terminal deoxynucleotidyl transferase, which lends biochemical support to the suggestion that some patients with chronic myelogenous leukemia undergo a lymphoblastic rather than a myeloblastic crisis.
Journal ArticleDOI
Distribution of Ia-like molecules on the surface of normal and leukemic human cells.
TL;DR: Antiserum to a glycoprotein antigen complex of 23,000 and 30,000 dalton subunits (p23,30), isolated and purified from a human lymphoblastoid B cell line, was shown to be highly specific for human bursal-equivalent-processed (B) cells, reactive with 15-20% of human Null cells, but completely unreactive with human thymus- Processed (T) cells.